Skip to main content

MW 266.29 Da, Purity >99%. Potent specific platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitor (IC50 values are 1.0 μM and 0.8 μM at PDGF α and β-receptors respectively). Cell-permeable.

Be the first to review this product! Submit a review

Images

Chemical Structure - AG 1296, protein tyrosine kinase inhibitor (AB141170), expandable thumbnail

Publications

Key facts

CAS number

146535-11-7

Purity

> 99%

Form

Solid

Molecular weight

266.29 Da

Molecular formula

C16H14N2O2

PubChem identifier

2049

Nature

Synthetic

Alternative names

Recommended products

MW 266.29 Da, Purity >99%. Potent specific platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitor (IC50 values are 1.0 μM and 0.8 μM at PDGF α and β-receptors respectively). Cell-permeable.

Key facts

Purity

> 99%

PubChem identifier

2049

Solubility

Soluble in DMSO to 100 mM. Soluble in ethanol to 10 mM.

Biochemical name

6,7-Dimethoxy-2-phenylquinoxaline

Biological description

Potent specific platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitor (IC50 values are 1.0 μM and 0.8 μM at PDGF α and β-receptors respectively). Cell-permeable.

Canonical SMILES

COC1=C(C=C2C(=C1)N=CC(=N2)C3=CC=CC=C3)OC

InChI

InChI=1S/C16H14N2O2/c1-19-15-8-12-13(9-16(15)20-2)18-14(10-17-12)11-6-4-3-5-7-11/h3-10H,1-2H3

InChIKey

QNOXYUNHIGOWNY-UHFFFAOYSA-N

IUPAC name

6,7-dimethoxy-2-phenylquinoxaline

Storage

Shipped at conditions

Ambient - Can Ship with Ice

Appropriate short-term storage conditions

-20°C

Appropriate long-term storage conditions

-20°C

Storage information

It is important to note that this product is reported to be light sensitive, Store in the dark, Store under desiccating conditions

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

JAK2 also known as Janus kinase 2 is a non-receptor tyrosine kinase with a mass of approximately 130 kDa. It is involved in cytokine receptor signaling and is broadly expressed in hematopoietic cells including stem cells and progenitor cells. TDP1 or tyrosyl-DNA phosphodiesterase 1 functions in DNA repair and is expressed in various tissues notably the brain and muscle. PDGFR alpha and beta are receptor tyrosine kinases involved in cellular proliferation differentiation and development. They are expressed in the mesenchymal cells and skin tissues. SMN or survival motor neuron protein interacts with Gemin proteins to form a complex. This complex is highly expressed in motor neurons and aids in the assembly of spliceosomal snRNPs.

Biological function summary

JAK2 mediates the action of growth factors and cytokines important for cell proliferation and hematopoiesis. It commonly partners with STAT proteins to control gene expression. TDP1 fixes DNA single-strand breaks apart from functioning independently it sometimes partners with other DNA repair proteins. PDGFR alpha and beta drive pathways controlling cell growth and migration often forming dimers upon ligand binding. SMN often in association with Gemin 1 plays a critical role in RNA processing and the assembly of the spliceosome complex which is indispensable for mRNA splicing.

Pathways

JAK2 occupies a central role in the JAK-STAT signaling pathway which impacts cell survival and apoptosis and interacts closely with STAT5. TDP1 is involved in the base excision repair pathway maintaining genome integrity and relating to PARP1 protein functions. PDGFR alpha and beta contribute significantly to the PI3K/AKT pathway and MAPK/ERK signaling involved in cell growth and proliferation operating in conjunction with proteins like PI3K and RAS. SMN’s involvement in the SMN-Gemin complex is critical for the biogenesis of snRNPs impacting RNA splicing pathways.

Associated diseases and disorders

Mutations in JAK2 are frequently linked to myeloproliferative neoplasms such as polycythemia vera often seen alongside mutations in the CALR gene. TDP1 when defective plays a role in neurological disorders including spinocerebellar ataxia with axonal neuropathy sometimes in conjunction with APTX mutations. PDGFR alpha and beta aberrations relate to cancers such as glioblastoma often found with IDH1 mutations. SMN mutations lead to spinal muscular atrophy where there is interaction with proteins like ubiquitin and survival-related factors in cells.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

1 product image

  • Chemical Structure - AG 1296, protein tyrosine kinase inhibitor (ab141170), expandable thumbnail

    Chemical Structure - AG 1296, protein tyrosine kinase inhibitor (ab141170)

    2D chemical structure image of ab141170, AG 1296, protein tyrosine kinase inhibitor

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com